The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

Shares of Pfizer Inc. PFE slid 2.44% to $25.99 Tuesday, on what proved to be an all-around poor trading session for the stock ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Summit Therapeutics stock is off to a slow start in 2025, but it still trades at a massive $13 billion valuation. The biotech ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...